Hims & Hers Health, Inc. Class A Common Stock (HIMS)
46.28
+4.87 (11.76%)
NYSE · Last Trade: Jun 26th, 6:11 PM EDT
Detailed Quote
Previous Close
41.41
Open
41.71
Bid
45.90
Ask
45.92
Day's Range
40.88 - 46.80
52 Week Range
13.47 - 72.98
Volume
64,165,572
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
48,249,209
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
NEW YORK, NY - June 26, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025 (the “Class Period”).
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO stated that it will continue to offer cheaper, compounded versions of GLP-1 weight-loss drugs. This statement comes on the heels of Novo Nordisk's recent termination of its partnership with Hims & Hers, where it was to supply its branded weight-loss drug, Wegovy. Novo Nordisk ended the collaboration citing concerns over Hims & Hers' promotion and sale of compounded drugs.
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company’s securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws.
Hims & Hers Health Inc. (NYSE: HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here's a look at what you need to know.
NEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE:HIMS) for potential violations of the federal securities laws.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025, inclusive (the “Class Period”). Hims investors have until August 25, 2025 to file a lead plaintiff motion.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025, inclusive (the “Class Period”). Hims investors have until August 25, 2025 to file a lead plaintiff motion.
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025. Hims describes itself as a “U.S.-based telehealth company that offers online access to health consultations and treatments.”
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) between April 29, 2025 and June 22, 2025, inclusive.
The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Sookdeo v. Hims & Hers Health, Inc., et al., Case No. 3:25-cv-05315, on behalf of persons and entities that purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Sookdeo v. Hims & Hers Health, Inc., et al., Case No. 3:25-cv-05315, on behalf of persons and entities that purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025, inclusive (the “Class Period”). Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
NEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE:HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LOS ANGELES, June 25, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws.
NEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Hims & Hers Health, Inc. (NYSE:HIMS) for potential violations of the federal securities laws.
NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS).
NEW YORK CITY, NY / ACCESS Newswire / June 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE:HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
